Építés alatt – nem éles oldal
Belépés
Fut, nem toboroz2. fázis

Evaluating Cannabidiol as a Novel Anticraving Medication for Alcohol Use Disorder

A legfontosabb adatok

Ki végzi
Centre for Addiction and Mental Health
Hol
Kanada1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Fut, nem toboroz
Fázis
2. fázis
Résztvevők
36 fő, tervezett
Kezdés
2024. aug. 16.
Várható befejezés
2027. jan. 31.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Oral solution
A regiszteradat frissítve
2026. november 2.

Ki vehet részt

Életkor
19 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 24 feltétel megnézéseKevesebb

Ki vehet részt

  • Meets DSM-5 criteria for AUD
  • Meets drinking criteria of average weekly consumption > 10 standard drinks for women and > 15 standard drinks for men over the past 90 days
  • Willing to take study medication and participate in laboratory sessions requiring self-administration of alcohol
  • Agrees not to use cannabis or illicit drugs during the study period
  • Able to communicate and provide informed consent in English
  • Alanine Aminotransferase (ALT) and Aspartate Transaminase (AST) level should not be more than 2 times the upper normal limit, and bilirubin should not be more than 1.5 times the upper normal limit
  • Enrolled in the Ontario Health Insurance Plan (OHIP)
  • Willing and able to safely abstain from alcohol for at least 12 hours prior to the eligibility and alcohol self-administration visit
  • Individuals who are capable of becoming pregnant: agree to the use of highly effective contraception during study participation and for an additional 28 days after the end of cannabidiol administration

Ki nem vehet részt

  • Having any clinical condition, drug sensitivity, or prior therapy which, in the investigator's opinion, makes the participant unsuitable for the study
  • Current medical conditions, prescriptions, or over the counter medications that interfere with receiving the study drug or alcohol (based on the study physician's assessment)
  • Recent recreational drug use (assessed via urine toxicology screen) other than alcohol and nicotine products
  • Currently in treatment for AUD (e.g. Alcoholics Anonymous, group therapy, individual therapy, on anticraving medication)
  • History of severe alcohol withdrawal including withdrawal seizures, alcoholic hallucinosis, or delirium tremens
  • Any history of seizures
  • Serious unstable medical condition, including severe hepatic abnormalities
  • Severe mental illness (e.g. active psychosis with ongoing delusions and/or hallucinations, active manic or hypomanic episodes, evidence of a major neurocognitive disorder, etc.) and other substance use disorders (moderate or severe; excluding tobacco use disorder) as determined by the qualified investigator
  • History of hypersensitivity to CBD
  • Clinical Institute Withdrawal Assessment (CIWA-Ar) score of 10 or above upon initial assessment
  • Experiencing active suicidal ideation within the past 1 month and/or suicide attempt within the past 6 months
  • Current use of CBD products or use of CBD products within the past month
  • Self-report of significant alcohol-induced flushing after 1-2 drinks (a proxy for aldehyde dehydrogenase deficiency)
  • Currently pregnant or breastfeeding or intending to become pregnant or breastfeed
  • Currently institutionalized which refers to a person who lives in an institutional collective dwelling, such as a hospital, nursing home or prison, including a resident under custody (e.g., patient or inmate)

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This human laboratory study aims to assess the effects of cannabidiol on alcohol consumption and craving in participants with alcohol use disorder. In this double-blind within-subject placebo-controlled crossover trial, participants will be randomized to receive both cannabidiol and placebo with a 2-week washout period separating the two treatment phases.

A vizsgálat 2 csoportja

  • CannabidiolA vizsgált kezelés

    10-day supply of 600 mg of CBD, taken orally twice daily

    Kezelés: Oral solution

  • PlaceboPlacebo, összehasonlításként

    10-day supply of 600 mg of placebo, taken orally twice daily

    Kezelés: Oral solution

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Evaluating Cannabidiol as a Novel Anticraving Medication for Alcohol Use Disorder: A Human Laboratory Study
A regiszteradat frissítve
2026. november 2.